• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

加勒比和美国心脏肿瘤学项目中患者表型、指南指导的建议依从性和心脏毒性发生率的比较。

Comparison of Patients' Phenotypes, Guideline-Directed Recommendations Compliance and Rates of Cardiotoxicity between Caribbean and United States Cardio-oncology Programs.

机构信息

Department of Cardiology, CEDIMAT Cardiovascular Center, Santo Domingo, Dominican Republic.

Section of Cardiology, Advocate Illinois Masonic Medical Center, Chicago, US.

出版信息

Glob Heart. 2022 Sep 20;17(1):67. doi: 10.5334/gh.1153. eCollection 2022.

DOI:10.5334/gh.1153
PMID:36199568
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9504154/
Abstract

BACKGROUND

Little is known about the characteristics of oncological patients, cancer therapy-induced cardiotoxicity, and guidelines-directed interventions in the Caribbean; analysis of cardio-oncology services may shed light on this and clarify links between ethnicity, cultural, and local socioeconomic factors.

OBJECTIVES

This study compared patients' phenotypes, adherence to guidelines recommendations, and patterns of cardiotoxicity between two cardio-oncology programs: one in the Dominican Republic (DR) and the other in Chicago IL, United States (US).

METHODS

Patients being considered for or treated with potentially cardiotoxic drugs were followed before, during, and after chemotherapy through both cardio-oncology clinics, where we recorded and compared clinical, demographic, and echocardiographic data.

RESULTS

We studied 597 consecutive patients, 330 (55%) from the DR and 267 (45%) from the US. DR vs. US mean age 55± 13/52 ± 13 years; female 77/87% (p < 0.001); breast cancer 57/73% (p < 0.001); treated with anthracyclines + taxanes 47/40% (p = 0.151); monoclonal antibodies + taxanes or platins 37/45% (p < 0.001). Cardiotoxicity DR vs. US occurred in 15/7% (p = 0.001); multivariate logistic regression (OR 2.29; 95% CI, 1.31-3.99; p < 0.005) did not identify age >60, HTN, DM, BMI, tobacco or chemotherapy as predictors. Compliance with ASCO guidelines was similar among both cohorts.

CONCLUSION

Compared to the US cohort, the Caribbean cohort of cancer patients has similar rates of CV risk factors but a higher likelihood of developing drug-induced LV dysfunction. Programs' compliance with ASCO guidelines was equivalent. While further research is needed to ascertain regional variations of cardiotoxicity, these findings underline the relevance of cardio-oncology services in nations with limited resources and high CV risk.

摘要

背景

对于加勒比地区的肿瘤患者特征、癌症治疗相关的心脏毒性以及指南指导的干预措施,我们知之甚少;对心脏肿瘤学服务进行分析可能有助于了解这些情况,并阐明种族、文化和当地社会经济因素之间的联系。

目的

本研究比较了两家心脏肿瘤学项目(一家位于多米尼加共和国(DR),另一家位于美国伊利诺伊州芝加哥市(US))的患者表型、对指南推荐的依从性以及心脏毒性模式。

方法

通过两家心脏肿瘤学诊所,对考虑或接受潜在心脏毒性药物治疗的患者进行前瞻性随访,我们记录并比较了临床、人口统计学和超声心动图数据。

结果

我们研究了 597 例连续患者,其中 330 例(55%)来自 DR,267 例(45%)来自 US。DR 与 US 的平均年龄分别为 55±13/52±13 岁;女性分别为 77/87%(p<0.001);乳腺癌分别为 57/73%(p<0.001);接受蒽环类药物+紫杉类药物治疗的分别为 47/40%(p=0.151);接受单克隆抗体+紫杉类药物或铂类药物治疗的分别为 37/45%(p<0.001)。DR 与 US 的心脏毒性发生率分别为 15/7%(p=0.001);多变量逻辑回归(OR 2.29;95%CI,1.31-3.99;p<0.005)未确定年龄>60 岁、高血压、糖尿病、BMI、吸烟或化疗是预测因素。两组患者对 ASCO 指南的依从性相似。

结论

与美国队列相比,加勒比癌症患者的心血管危险因素发生率相似,但发生药物诱导的左心室功能障碍的可能性更高。各项目对 ASCO 指南的依从性相当。尽管需要进一步研究以确定心脏毒性的区域差异,但这些发现强调了在资源有限和心血管风险较高的国家开展心脏肿瘤学服务的重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0292/9504154/89bbd2687da8/gh-17-1-1153-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0292/9504154/89bbd2687da8/gh-17-1-1153-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0292/9504154/89bbd2687da8/gh-17-1-1153-g1.jpg

相似文献

1
Comparison of Patients' Phenotypes, Guideline-Directed Recommendations Compliance and Rates of Cardiotoxicity between Caribbean and United States Cardio-oncology Programs.加勒比和美国心脏肿瘤学项目中患者表型、指南指导的建议依从性和心脏毒性发生率的比较。
Glob Heart. 2022 Sep 20;17(1):67. doi: 10.5334/gh.1153. eCollection 2022.
2
Cardiotoxicity and Cardiac Monitoring Among Chemotherapy-Treated Breast Cancer Patients.化疗治疗乳腺癌患者的心脏毒性和心脏监测。
JACC Cardiovasc Imaging. 2018 Aug;11(8):1084-1093. doi: 10.1016/j.jcmg.2018.06.005.
3
A randomized trial to evaluate the impact of exercise-based cardiac rehabilitation for the prevention of chemotherapy-induced cardiotoxicity in patients with breast cancer: ONCORE study protocol.一项评估基于运动的心脏康复对预防乳腺癌患者化疗引起的心脏毒性影响的随机试验:ONCORE 研究方案。
BMC Cardiovasc Disord. 2021 Apr 7;21(1):165. doi: 10.1186/s12872-021-01970-2.
4
Age-Related Considerations in Cardio-Oncology.心脏肿瘤学中的年龄相关考虑因素。
J Cardiovasc Pharmacol Ther. 2021 Mar;26(2):103-113. doi: 10.1177/1074248420968689. Epub 2020 Oct 30.
5
Longitudinal changes of right ventricular deformation mechanics during trastuzumab therapy in breast cancer patients.曲妥珠单抗治疗乳腺癌患者过程中心脏右室变形力学的纵向变化。
Eur J Heart Fail. 2019 Apr;21(4):529-535. doi: 10.1002/ejhf.1385. Epub 2019 Feb 27.
6
Cardiotoxic effects of anthracycline-based therapy: what is the evidence and what are the potential harms?蒽环类药物治疗的心脏毒性作用:有哪些证据和潜在危害?
Lancet Oncol. 2017 Aug;18(8):e445-e456. doi: 10.1016/S1470-2045(17)30535-1. Epub 2017 Jul 26.
7
Personalized Decision Making in Early Stage Breast Cancer: Applying Clinical Prediction Models for Anthracycline Cardiotoxicity and Breast Cancer Mortality Demonstrates Substantial Heterogeneity of Benefit-Harm Trade-off.早期乳腺癌的个体化决策:应用临床预测模型评估蒽环类药物心脏毒性和乳腺癌死亡率显示获益-风险权衡存在显著异质性。
Clin Breast Cancer. 2019 Aug;19(4):259-267.e1. doi: 10.1016/j.clbc.2019.04.012. Epub 2019 May 2.
8
Baseline cardio-oncologic risk assessment in breast cancer women and occurrence of cardiovascular events: The HFA/ICOS risk tool in real-world practice.乳腺癌女性的基线心脏肿瘤学风险评估与心血管事件的发生:现实世界实践中的HFA/ICOS风险工具
Int J Cardiol. 2022 Feb 15;349:134-137. doi: 10.1016/j.ijcard.2021.11.059. Epub 2021 Nov 27.
9
Cardiotoxicity of Contemporary Breast Cancer Treatments.当代乳腺癌治疗的心脏毒性。
Curr Treat Options Oncol. 2019 May 9;20(6):51. doi: 10.1007/s11864-019-0646-1.
10
New Insights on the Toxicity on Heart and Vessels of Breast Cancer Therapies.乳腺癌治疗药物对心脏和血管毒性的新认识。
Med Sci (Basel). 2022 May 25;10(2):27. doi: 10.3390/medsci10020027.

本文引用的文献

1
Cardiac imaging in cardiotoxicity: a focus on clinical practice.心脏毒性中的心脏成像:聚焦临床实践
Heart Fail Rev. 2021 Sep;26(5):1175-1187. doi: 10.1007/s10741-020-09952-w.
2
Cardiotoxicity of Anthracyclines.蒽环类药物的心脏毒性
Front Cardiovasc Med. 2020 Mar 18;7:26. doi: 10.3389/fcvm.2020.00026. eCollection 2020.
3
Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer.随机试验:依那普利与卡维地洛预防乳腺癌患者曲妥珠单抗心脏毒性
J Am Coll Cardiol. 2019 Jun 11;73(22):2859-2868. doi: 10.1016/j.jacc.2019.03.495.
4
Beta-blockers for the primary prevention of anthracycline-induced cardiotoxicity: a meta-analysis of randomized controlled trials.β受体阻滞剂在预防蒽环类药物诱导的心脏毒性中的作用:一项随机对照试验的荟萃分析。
BMC Pharmacol Toxicol. 2019 Apr 25;20(1):18. doi: 10.1186/s40360-019-0298-6.
5
Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods.估算 2018 年全球癌症发病率和死亡率:GLOBOCAN 来源和方法。
Int J Cancer. 2019 Apr 15;144(8):1941-1953. doi: 10.1002/ijc.31937. Epub 2018 Dec 6.
6
Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial.卡维地洛预防化疗相关性心脏毒性:CECCY 试验。
J Am Coll Cardiol. 2018 May 22;71(20):2281-2290. doi: 10.1016/j.jacc.2018.02.049. Epub 2018 Mar 11.
7
Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline.成人癌症幸存者心功能障碍的预防和监测:美国临床肿瘤学会临床实践指南。
J Clin Oncol. 2017 Mar 10;35(8):893-911. doi: 10.1200/JCO.2016.70.5400. Epub 2016 Dec 5.
8
Cancer treatment and survivorship statistics, 2016.癌症治疗和生存统计,2016 年。
CA Cancer J Clin. 2016 Jul;66(4):271-89. doi: 10.3322/caac.21349. Epub 2016 Jun 2.
9
Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol.辅助性乳腺癌治疗期间心脏功能障碍的预防(PRADA):一项关于坎地沙坦和美托洛尔的2×2析因、随机、安慰剂对照、双盲临床试验。
Eur Heart J. 2016 Jun 1;37(21):1671-80. doi: 10.1093/eurheartj/ehw022. Epub 2016 Feb 21.
10
Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study.成年期发病癌症幸存者中的心血管疾病:一项基于社区的回顾性队列研究。
J Clin Oncol. 2016 Apr 1;34(10):1122-30. doi: 10.1200/JCO.2015.64.0409. Epub 2016 Feb 1.